Top

Published in:

01-12-2012 | Original Article

Prevalence of sarcopenia and relevance of body composition, physiological function, fatigue, and health-related quality of life in patients before allogeneic hematopoietic stem cell transplantation

Authors: Shinichiro Morishita, Katsuji Kaida, Takashi Tanaka, Yusuke Itani, Kazuhiro Ikegame, Masaya Okada, Shinichi Ishii, Norihiko Kodama, Hiroyasu Ogawa, Kazuhisa Domen

Published in: Supportive Care in Cancer | Issue 12/2012

Abstract

Purpose

Cachexia in patients with hematological malignancies is often related to sarcopenia. We believe that allogeneic hematopoietic stem cell transplant (allo-HSCT) patients often exhibit sarcopenia prior to transplantation. Here, we aimed to investigate the prevalence of sarcopenia and its relationship with body composition, physiological function, nutrition, fatigue, and health-related quality of life (QOL) in patients before allo-HSCT. We further investigated the confounding factors associated with sarcopenia.

Methods

We included 164 patients with allo-HSCT in this study. Body composition, handgrip, knee extensor strength, and 6-min walk test were evaluated. Furthermore, fatigue, nutritional status, and health-related QOL were also evaluated.

Results

Eighty-three patients (50.6 %) enrolled in our study had sarcopenia prior to allo-HSCT. Patients with sarcopenia experienced decreased muscular strength and increased fatigue compared with patients without sarcopenia (p < 0.05). Patients with sarcopenia showed significantly lower scores in physical functioning, bodily pain, and vitality in health-related QOL than those without sarcopenia. Multivariate regression analysis revealed that only gender and body mass index were significantly related to sarcopenia (gender, odds ratio, 3.09; body mass index, odds ratio, 0.70; p < 0.01).

Conclusions

Sarcopenia is common in patients before allo-HSCT and related to low muscle strength, fatigue, and health-related QOL. Male patients may be more susceptible to sarcopenia than female patients before allo-HSCT. Further study of rehabilitation with gender insight is warranted for patients receiving allo-HSCT.

Tisdale MJ (2009) Mechanisms of cancer cachexia. Physiol Rev 89:381–410PubMedCrossRef

Bosaeus I, Daneryd P, Svanberg E, Lundholm K (2001) Dietary intake and resting energy expenditure in relation to weight loss in unselected cancer patients. Int J Cancer 93:380–383PubMedCrossRef

Lieffers JR, Mourtzakis M, Hall KD, McCargar LJ, Prado CM, Baracos VE (2009) A viscerally driven cachexia syndrome in patients with advanced colorectal cancer: contributions of organ and tumor mass to whole-body energy demands. Am J Clin Nutr 89:1173–1179PubMedCrossRef

Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, Baracos VE (2008) Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 9:629–635PubMedCrossRef

Muscaritoli M, Anker SD, Argilés J, Aversa Z, Bauer JM, Biolo G, Boirie Y, Bosaeus I, Cederholm T, Costelli P, Fearon KC, Laviano A, Maggio M, Rossi Fanelli F, Schneider SM, Schols A, Sieber CC (2010) Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) “cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics”. Clin Nutr 29:154–159PubMedCrossRef

Prado CM, Baracos VE, McCargar LJ, Mourtzakis M, Mulder KE, Reiman T, Butts CA, Scarfe AG, Sawyer MB (2007) Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res 13:3264–3268PubMedCrossRef

Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, Mackey JR, Koski S, Pituskin E, Sawyer MB (2009) Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 15:2920–2926PubMedCrossRef

Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, Garry PJ, Lindeman RD (1998) Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 147:755–763PubMedCrossRef

Chien MY, Kuo HK, Wu YT (2010) Sarcopenia, cardiopulmonary fitness, and physical disability in community-dwelling elderly people. Phys Ther 90:1277–1287PubMedCrossRef

10.

Janssen I, Heymsfield SB, Ross R (2002) Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc 50:889–896PubMedCrossRef

11.

Molassiotis A (2003) Anorexia and weight loss in long-term survivors of haematological malignancies. J Clin Nurs 12:925–927PubMedCrossRef

12.

Morishita S, Kaida K, Ikegame K, Yoshihara S, Taniguchi K, Okada M, Kodama N, Ogawa H, Domen K (2012) Impaired physiological function and health-related QOL in patients before hematopoietic stem-cell transplantation. Support Care Cancer 20:821–829. doi:10.1007/s00520-011-1156-2 PubMedCrossRef

13.

Cruz-Jentoft AJ, Landi F, Topinková E, Michel JP (2010) Understanding sarcopenia as a geriatric syndrome. Curr Opin Clin Nutr Metab Care 13:1–7PubMedCrossRef

14.

Janssen I, Heymsfield SB, Baumgartner RN, Ross R (2000) Estimation of skeletal muscle mass by bioelectrical impedance analysis. J Appl Physiol 89:465–471PubMed

15.

Chien MY, Huang TY, Wu YT (2008) Prevalence of sarcopenia estimated using a bioelectrical impedance analysis prediction equation in community-dwelling elderly people in Taiwan. J Am Geriatr Soc 56:1710–1715PubMedCrossRef

16.

Katoh M, Yamasaki H (2009) Comparison of reliability of isometric leg muscle strength measurements made using a hand-held dynamometer with and without a restraining belt. J Phys Ther Sci 21:37–42CrossRef

17.

Katoh M, Yamasaki H (2009) Test-retest reliability of isometric leg muscle strength measurements made using a hand-held dynamometer restrained by a belt: comparisons during and between sessions. J Phys Ther Sci 21:239–243CrossRef

18.

ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories (2002) ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166:111–117

19.

Sciurba F, Criner GJ, Lee SM, Mohsenifar Z, Shade D, Slivka W, Wise RA, National Emphysema Treatment Trial Research Group (2003) Six-minute walk distance in chronic obstructive pulmonary disease: reproducibility and effect of walking course layout and length. Am J Respir Crit Care Med 167:1522–1527PubMedCrossRef

20.

Piper BF, Dibble SL, Dodd MJ, Weiss MC, Slaughter RE, Paul SM (1998) The revised Piper Fatigue Scale: psychometric evaluation in women with breast cancer. Oncol Nurs Forum 25:677–684PubMed

21.

Fukuhara S, Ware JE Jr, Kosinski M, Wada S, Gandek B (1998) Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey. J Clin Epidemiol 51:1045–1053PubMedCrossRef

22.

Fukuhara S, Bito S, Green J, Hsiao A, Kurokawa K (1998) Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan. J Clin Epidemiol 51:1037–1044PubMedCrossRef

23.

Fukuhara S, Suzukamo Y (2004) Manual of SF-36v2 Japanese version. Institute for Health Outcomes and Process Evaluation Research, Kyoto

24.

Syrjala KL, Stover AC, Yi JC, Artherholt SB, Abrams JR (2010) Measuring social activities and social function in long-term cancer survivors who received hematopoietic stem cell transplantation. Psychooncology 19:462–471PubMedCrossRef

25.

Guimarães FA, Santos MA, Oliveira EA (2008) Quality of life of patients with autoimmune diseases submitted to bone marrow transplantation: a longitudinal study. Rev Lat Am Enfermagem 16:856–863PubMedCrossRef

26.

Lau AK, Chang CH, Tai JW, Eremenco S, Liang R, Lie AK, Fong DY, Lau CM (2002) Translation and validation of the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) Version 4 quality of life instrument into traditional Chinese. Bone Marrow Transplant 29:41–49PubMedCrossRef

27.

Tan BH, Birdsell LA, Martin L, Baracos VE, Fearon KC (2009) Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res 15:6973–6979PubMedCrossRef

28.

Antoun S, Baracos VE, Birdsell L, Escudier B, Sawyer MB (2010) Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol 21:1594–1598PubMedCrossRef

29.

Boirie Y (2009) Physiopathological mechanism of sarcopenia. J Nutr Health Aging 13:717–723PubMedCrossRef

30.

Kilgour RD, Vigano A, Trutschnigg B, Hornby L, Lucar E, Bacon SL, Morais JA (2010) Cancer-related fatigue: the impact of skeletal muscle mass and strength in patients with advanced cancer. J Cachexia Sarcopenia Muscle 1:177–185PubMedCrossRef

31.

Aulino P, Berardi E, Cardillo VM, Rizzuto E, Perniconi B, Ramina C, Padula F, Spugnini EP, Baldi A, Faiola F, Adamo S, Coletti D (2010) Molecular, cellular and physiological characterization of the cancer cachexia-inducing C26 colon carcinoma in mouse. BMC Cancer 10:363PubMedCrossRef

32.

Kull M, Kallikorm R, Lember M (2012) Impact of a new sarco-osteopenia definition on health-related quality of life in a population-based cohort in Northern Europe. J Clin Densitom 15:32–38. doi:10.1016/j.jocd.2011.08.007 PubMedCrossRef

33.

Landi F, Liperoti R, Fusco D, Mastropaolo S, Quattrociocchi D, Proia A, Tosato M, Bernabei R, Onder G (2012) Sarcopenia and mortality among older nursing home residents. J Am Med Dir Assoc 13:121–126. doi:10.1016/j.jamda.2011.07.004 PubMedCrossRef

34.

Pietrobelli A, Rubiano F, St-Onge MP, Heymsfield SB (2004) New bioimpedance analysis system: improved phenotyping with whole-body analysis. Eur J Clin Nutr 58:1479–1484PubMedCrossRef

Title: Prevalence of sarcopenia and relevance of body composition, physiological function, fatigue, and health-related quality of life in patients before allogeneic hematopoietic stem cell transplantation
Authors: Shinichiro Morishita
Katsuji Kaida
Takashi Tanaka
Yusuke Itani
Kazuhiro Ikegame
Masaya Okada
Shinichi Ishii
Norihiko Kodama
Hiroyasu Ogawa
Kazuhisa Domen
Publication date: 01-12-2012
Publisher: Springer-Verlag
Published in: Supportive Care in Cancer / Issue 12/2012
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-012-1460-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2012

Identifying the informational and psychosocial needs of Chinese immigrant cancer patients: a focus group study

Short post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia

Oral bacteria and yeasts in relationship to oral ulcerations in hematopoietic stem cell transplant recipients

Acceptability and feasibility of family use of The Cellie Cancer Coping Kit

Accrual in supportive care trials in pediatric oncology, a challenge!

Probiotic factors partially prevent changes to caspases 3 and 7 activation and transepithelial electrical resistance in a model of 5-fluorouracil-induced epithelial cell damage

Keynote webinar | Spotlight on antibody–drug conjugates in cancer